Sarcopenia - Market Insights, Epidemiology and Market Forecast -2023-7 MM
This report can be delivered to the clients within 24 Hours
DelveInsight’s “Sarcopenia - Market Insights, Epidemiology and Market Forecast-2023-7 MM” Report provides an overview of the disease and global market size of the Sarcopenia for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023.
Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most people begin to lose modest amounts of muscle mass after age 30, but the resulting loss of strength increases exponentially with age. Of the contributory factors relating to the development of sarcopenia inadequate protein intake, increased splanchnic extraction of amino acids, decreased muscular response to postprandial anabolic stimuli and vitamin D deficiency are directly related to nutrition.
According to DelveInsight, the market size of Sarcopenia in 7 MM is estimated to be USD XX Million by 2023 at a CAGR of 2.36% for the forecast period i.e., 2013-2023. Also the prevalence cases in 7 MM are expected to increase and reach up to 42,969,489 cases by year 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
SCOPE
The report will help in developing business strategies by understanding the trends shaping and driving the Sarcopenia market.
Organize sales and marketing efforts by identifying the best opportunities for Sarcopenia in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
To understand the future market competition in the 7MM market of Sarcopenia and Insightful review of the key market drivers and barriers.
To understand the regulatory scenario in major markets.
The Report also covers the detailed historical and forecasted Sarcopenia market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
DelveInsight’s “Sarcopenia - Market Insights, Epidemiology and Market Forecast-2023-7 MM” Report provides an overview of the disease and global market size of the Sarcopenia for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023.
Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most people begin to lose modest amounts of muscle mass after age 30, but the resulting loss of strength increases exponentially with age. Of the contributory factors relating to the development of sarcopenia inadequate protein intake, increased splanchnic extraction of amino acids, decreased muscular response to postprandial anabolic stimuli and vitamin D deficiency are directly related to nutrition.
According to DelveInsight, the market size of Sarcopenia in 7 MM is estimated to be USD XX Million by 2023 at a CAGR of 2.36% for the forecast period i.e., 2013-2023. Also the prevalence cases in 7 MM are expected to increase and reach up to 42,969,489 cases by year 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
SCOPE
The report will help in developing business strategies by understanding the trends shaping and driving the Sarcopenia market.
Organize sales and marketing efforts by identifying the best opportunities for Sarcopenia in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
To understand the future market competition in the 7MM market of Sarcopenia and Insightful review of the key market drivers and barriers.
To understand the regulatory scenario in major markets.
The Report also covers the detailed historical and forecasted Sarcopenia market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
Report Introduction
Sarcopenia: Overview
Introduction
Pathophysiology
Symptoms
Diagnosis
Sarcopenia categories and stages
EWGSOP Conceptual Stages of Sarcopenia
Treatment
Challenges
Unmet Need
Epidemiology of Sarcopenia in 7MM
Epidemiology and Patient Population
Assumptions and Caveats
Prevalent Population of Sarcopenia in 7MM
United States
Europe
United Kingdom
France
Italy
Spain
Germany
Japan
Pipeline Drugs in Development
Enobosarm: GTX, Inc.
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
REGN-1033: Regeneron Pharmaceuticals
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
LY-2495655: Eli Lilly and Company
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
Testosterone Enanthate + Finasteride: Endo Pharmaceuticals
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
BYM338: Novartis AG
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
Sarconeos: Biophytis
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
Global Market Scenario for Sarcopenia
Sarcopenia: Country-Wise Market Analysis
7 MAJOR MARKET SIZE OF SARCOPENIA (2013-2023)
Global Market Size by Geography
United States
Market size of Europe
United Kingdom
France
Italy
Spain
Germany
Japan
Market Drivers and Market Barriers for Sarcopenia
Future Prospects for Sarcopenia
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Sarcopenia: Overview
Introduction
Pathophysiology
Symptoms
Diagnosis
Sarcopenia categories and stages
EWGSOP Conceptual Stages of Sarcopenia
Treatment
Challenges
Unmet Need
Epidemiology of Sarcopenia in 7MM
Epidemiology and Patient Population
Assumptions and Caveats
Prevalent Population of Sarcopenia in 7MM
United States
Europe
United Kingdom
France
Italy
Spain
Germany
Japan
Pipeline Drugs in Development
Enobosarm: GTX, Inc.
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
REGN-1033: Regeneron Pharmaceuticals
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
LY-2495655: Eli Lilly and Company
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
Testosterone Enanthate + Finasteride: Endo Pharmaceuticals
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
BYM338: Novartis AG
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
Sarconeos: Biophytis
Product Description
Clinical Development
Advantages & Disadvantages
Product Profile
Global Market Scenario for Sarcopenia
Sarcopenia: Country-Wise Market Analysis
7 MAJOR MARKET SIZE OF SARCOPENIA (2013-2023)
Global Market Size by Geography
United States
Market size of Europe
United Kingdom
France
Italy
Spain
Germany
Japan
Market Drivers and Market Barriers for Sarcopenia
Future Prospects for Sarcopenia
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
LIST OF TABLES
Table 1: Prevalent Population of Sarcopenia in 7MM (2013-2023)
Table 2: Prevalent Population of Sarcopenia in United States (2013-2023)
Table 3: Prevalent Population of Sarcopenia in United Kingdom (2013-2023)
Table 4: Prevalent Population of Sarcopenia in France (2013-2023)
Table 5: Prevalent Population of Sarcopenia in Italy (2013-2023)
Table 6: Prevalent Population of Sarcopenia in Spain (2013-2023)
Table 7: Prevalent Population of Sarcopenia in Germany (2013-2023)
Table 8: Prevalent Population of Sarcopenia in Japan (2013-2023)
Table 9: Pipeline Drugs and Mechanism of Action, 2016
Table 10: Total 7 Major Market size of Sarcopenia in USD Million (2013-2023)
Table 11: United States Market Size of Sarcopenia in USD, Million (2013-2023)
Table 12: United Kingdom Market Size of Sarcopenia in USD, Million (2013-2023)
Table 13: France Market Size of Sarcopenia in USD, Million (2013-2023)
Table 14: Italy Market Size of Sarcopenia in USD, Million (2013-2023)
Table 15: Spain Market Size of Sarcopenia in USD, Million (2013-2023)
Table 16: Germany Market Size of Sarcopenia in USD, Million (2013-2023)
Table 17:Japan Market Size of Sarcopenia in USD, Million (2013-2023)
Table 1: Prevalent Population of Sarcopenia in 7MM (2013-2023)
Table 2: Prevalent Population of Sarcopenia in United States (2013-2023)
Table 3: Prevalent Population of Sarcopenia in United Kingdom (2013-2023)
Table 4: Prevalent Population of Sarcopenia in France (2013-2023)
Table 5: Prevalent Population of Sarcopenia in Italy (2013-2023)
Table 6: Prevalent Population of Sarcopenia in Spain (2013-2023)
Table 7: Prevalent Population of Sarcopenia in Germany (2013-2023)
Table 8: Prevalent Population of Sarcopenia in Japan (2013-2023)
Table 9: Pipeline Drugs and Mechanism of Action, 2016
Table 10: Total 7 Major Market size of Sarcopenia in USD Million (2013-2023)
Table 11: United States Market Size of Sarcopenia in USD, Million (2013-2023)
Table 12: United Kingdom Market Size of Sarcopenia in USD, Million (2013-2023)
Table 13: France Market Size of Sarcopenia in USD, Million (2013-2023)
Table 14: Italy Market Size of Sarcopenia in USD, Million (2013-2023)
Table 15: Spain Market Size of Sarcopenia in USD, Million (2013-2023)
Table 16: Germany Market Size of Sarcopenia in USD, Million (2013-2023)
Table 17:Japan Market Size of Sarcopenia in USD, Million (2013-2023)
LIST OF FIGURES
Figure 1: Mechanisms of Sarcopenia
Figure 2: EWGSOP Screening Algorithm
Figure 3: Prevalent Population of Sarcopenia in 7MM (2013-2023)
Figure 4: Prevalent Population of Sarcopenia in United States (2013-2023)
Figure 5: Prevalent Population of Sarcopenia in United Kingdom (2013-2023)
Figure 6: Prevalent Population of Sarcopenia in France (2013-2023)
Figure 7: Prevalent Population of Sarcopenia in Italy (2013-2023)
Figure 8: Prevalent Population of Sarcopenia in Spain (2013-2023)
Figure 9:Prevalent Population of Sarcopenia in Germany (2013-2023)
Figure 10:Prevalent Population of Sarcopenia in Japan (2013-2023)
Figure 11: Total 7 Major Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 12: United States Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 13: United Kingdom Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 14: France Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 15: Italy Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 16: Spain Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 17: Germany Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 18:Japan Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 1: Mechanisms of Sarcopenia
Figure 2: EWGSOP Screening Algorithm
Figure 3: Prevalent Population of Sarcopenia in 7MM (2013-2023)
Figure 4: Prevalent Population of Sarcopenia in United States (2013-2023)
Figure 5: Prevalent Population of Sarcopenia in United Kingdom (2013-2023)
Figure 6: Prevalent Population of Sarcopenia in France (2013-2023)
Figure 7: Prevalent Population of Sarcopenia in Italy (2013-2023)
Figure 8: Prevalent Population of Sarcopenia in Spain (2013-2023)
Figure 9:Prevalent Population of Sarcopenia in Germany (2013-2023)
Figure 10:Prevalent Population of Sarcopenia in Japan (2013-2023)
Figure 11: Total 7 Major Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 12: United States Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 13: United Kingdom Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 14: France Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 15: Italy Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 16: Spain Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 17: Germany Market Size of Sarcopenia in USD, Million (2013-2023)
Figure 18:Japan Market Size of Sarcopenia in USD, Million (2013-2023)
